Abstract 475P
Background
Lobectomy had long been the established gold standard curative surgery for early stage lung cancer. With emerging evidence on the non-inferior outcome of segmentectomy, we had been performing segmentectomy on selected stage 1 lung cancer patients in our institution since 2012. It is timely for us to review our experience with segmentectomy in this group of patients.
Methods
We reviewed all the patients in our institution who underwent curative lung resection in a mixed Asian population over a 12-year period between 2006 and 2017. Staging was based on AJCC TNM 6th edition for patients before 2010 and 7th edition for patients after 2010. Only patients with stage 1 lung cancer were included in our study.
Results
269 patients were included in our study. 39 patients (14.5%) underwent segmentectomy, 225 patients (83.6%) underwent lobectomy and 5 patients (1.9%) underwent pneumonectomy. None of the segmentectomy cases had any visceral pleura or lymph node involvement reported on final histology. There was no significant difference in the mean duration of follow up between patients who had segmentectomy (5.37 +/- 2.94 years) and those who had lobectomy and above (6.41 +/- 3.43 years) (p = 0.083). Segmentectomy was associated with a significantly lower recurrence rate (OR 0.19, 95% CI 0.05-0.75) and a 5-year disease free survival of 96.6% compared to 73.1% in lobectomy patients (p = 0.002). The time to recurrence was also longer in segmentectomy patients (mean 4.25 +/- 3.53 years vs 2.78 +/- 2.23 years) but this was not statistically significant (p = 0.371). There was no significance difference in the short term 30-day survival between patients who underwent segmentectomy and lobectomy and above. There was also no significant difference in survival at 1, 3 and 5 years between the 2 groups of patients.
Conclusions
Our study demonstrated good disease-free survival in patients who underwent segmentectomy with no significant differences in overall survival. It is likely that careful selection of patients will produce equally good outcome in segmentectomy patients and this can give us renewed confidence in moving forward with lung preservation surgery for patients with early stage lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract
102P - Enhancing colorectal cancer prevention in high-risk populations through faecal immunochemical test surveillance
Presenter: Li Xie
Session: Poster Display
Resources:
Abstract
103P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort A
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
104P - The value of functional MR-imaging signature model for early prediction of chemotherapy response and its guidance for regimen adjustment to improve efficacy
Presenter: Wenhua Li
Session: Poster Display
Resources:
Abstract
105P - A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors
Presenter: Weijian Guo
Session: Poster Display
Resources:
Abstract
106P - Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRASG12C mutation: Updated results from a pooled analysis of two phase I studies
Presenter: Ying Yuan
Session: Poster Display
Resources:
Abstract
107P - Tumor-stromal ratio in a new age fibroblast activated protein PET imaging as a biomarker for prediction of response to neoadjuvant chemoradiotherapy in carcinoma rectum
Presenter: swetha Suresh
Session: Poster Display
Resources:
Abstract
108P - Detection of HER2 overexpression in colorectal cancer: Comparison of a HANDLE classic NGS panel with standard IHC/FISH
Presenter: Lijuan Luan
Session: Poster Display
Resources:
Abstract
109P - Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular status
Presenter: Andrea Pretta
Session: Poster Display
Resources:
Abstract
110P - The correlation between multi-dimensional characteristics of circulating tumor cells (CTC) and treatment response in patients with initially unresectable metastatic colorectal cancer
Presenter: Yu Liu
Session: Poster Display
Resources:
Abstract